$2.67
arrow_drop_down1.30%Key Stats | |
---|---|
Open | $2.39 |
Prev. Close | $2.37 |
EPS | 1.72 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $34.95M |
LOW | HIGH | |
---|---|---|
Day Range | 2.07 | 2.73 |
52 Week Range | 1.57 | 4.48 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | 1.72 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Analyst Scoreboard: 4 Ratings For VYNE Therapeutics
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now